Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, Lang Y, Lee WL, Zhou J, Bulitta JB, Nation RL, Boyce JD, Oliver A, Landersdorfer CB. Tait JR, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. Epub 2023 Jul 10. Antimicrob Agents Chemother. 2023. PMID: 37428034 Free PMC article.
Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
Bergen PJ, Bulitta JB, Kirkpatrick CM, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Lipman J, Roberts JA, Landersdorfer CB. Bergen PJ, et al. Among authors: rogers ke. J Antimicrob Chemother. 2016 Sep;71(9):2509-20. doi: 10.1093/jac/dkw153. Epub 2016 May 26. J Antimicrob Chemother. 2016. PMID: 27231278
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB. Bergen PJ, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02642-16. doi: 10.1128/AAC.02642-16. Print 2017 May. Antimicrob Agents Chemother. 2017. PMID: 28264846 Free PMC article.
Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.
Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, Nation RL, Bulitta JB. Landersdorfer CB, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02053-17. doi: 10.1128/AAC.02053-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29339388 Free PMC article.
Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB. Landersdorfer CB, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02055-17. doi: 10.1128/AAC.02055-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29437610 Free PMC article.
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB. Yadav R, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e00078-18. doi: 10.1128/AAC.00078-18. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29463528 Free PMC article.
Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB. Rees VE, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01150-18. doi: 10.1128/AAC.01150-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30104278 Free PMC article.
Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R, Bergen PJ, Rogers KE, Kirkpatrick CMJ, Wallis SC, Huang Y, Bulitta JB, Paterson DL, Lipman J, Nation RL, Roberts JA, Landersdorfer CB. Yadav R, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01679-19. doi: 10.1128/AAC.01679-19. Print 2019 Dec 20. Antimicrob Agents Chemother. 2019. PMID: 31636062 Free PMC article.
Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance.
Agyeman AA, Rogers KE, Tait JR, Bergen PJ, Kirkpatrick CM, Wallis SC, Bulitta JB, Paterson DL, Lipman J, Nation RL, Roberts JA, Landersdorfer CB. Agyeman AA, et al. Among authors: rogers ke. Clin Pharmacol Ther. 2021 Apr;109(4):1104-1115. doi: 10.1002/cpt.2191. Epub 2021 Mar 12. Clin Pharmacol Ther. 2021. PMID: 33550617
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model.
Tait JR, Bilal H, Rogers KE, Lang Y, Kim TH, Zhou J, Wallis SC, Bulitta JB, Kirkpatrick CMJ, Paterson DL, Lipman J, Bergen PJ, Roberts JA, Nation RL, Landersdorfer CB. Tait JR, et al. Among authors: rogers ke. Antibiotics (Basel). 2022 Jan 13;11(1):101. doi: 10.3390/antibiotics11010101. Antibiotics (Basel). 2022. PMID: 35052977 Free PMC article.
54 results